Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.

    Article  CAS  PubMed  Google Scholar 

  2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  3. Dong M, Blobe GC . Role of transforming growth factor-β in hematological malignancies. Blood 2006; 107: 4586–4596.

    Article  Google Scholar 

  4. Coffman JA . Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 2003; 27: 315–324.

    Article  CAS  PubMed  Google Scholar 

  5. Otto F, Stock M, Fliegauf M, Fenaux P, Preudhomme C, Lübbert M . Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia. Leukemia 2003; 17: 1677–1678.

    Article  CAS  PubMed  Google Scholar 

  6. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402–409.

    Article  CAS  PubMed  Google Scholar 

  7. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113–124.

    Article  CAS  PubMed  Google Scholar 

  8. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC et al. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 2006; 25: 7646–7649.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

HPK is a member of the Johnsson Cancer Center, the Molecular Biology Institute of UCLA and has the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. This work was also supported, in part, by a fellowship from the Deutsche Forschungsgemeinschaft to CIM (MU 1809/1), and by an International Visiting Fellowship from Leukaemia Research Fund (UK) to QTL (no. 0340).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C I Müller.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, C., Luong, Q., Shih, LY. et al. Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals. Leukemia 22, 1773–1778 (2008). https://doi.org/10.1038/leu.2008.41

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.41

This article is cited by

Search

Quick links